Yuho Najima

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1873487/publications.pdf

Version: 2024-02-01

114 papers 3,052 citations

346980 22 h-index 190340 53 g-index

114 all docs

114 docs citations

times ranked

114

5742 citing authors

#	Article	IF	CITATIONS
1	Prognostic impact of <i>CEBPA</i> bZIP domain mutation in acute myeloid leukemia. Blood Advances, 2022, 6, 238-247.	2.5	61
2	Retrospective comparison of hematopoietic stem cell transplantation following reduced-intensity conditioning with fludarabine/low-dose melphalan plus 4ÂGy TBI versus fludarabine/ busulfan plus 4ÂGy TBI. International Journal of Hematology, 2022, 115, 244-254.	0.7	0
3	Antithymocyte Globulin Potentially Could Overcome an Adverse Effect of Acute Graft-versus-Host Disease in Matched-Related Peripheral Blood Stem Cell Transplantation. Transplantation and Cellular Therapy, 2022, 28, 153.e1-153.e11.	0.6	2
4	Prognostic impact of TP53 mutation, monosomal karyotype, and prior myeloid disorder in nonremission acute myeloid leukemia at allo-HSCT. Bone Marrow Transplantation, 2021, 56, 334-346.	1.3	9
5	A multicenter phase II study of intrabone single-unit cord blood transplantation without antithymocyte globulin. Annals of Hematology, 2021, 100, 743-752.	0.8	3
6	Effect of methotrexate dose in graft-versus-host disease prophylaxis after single-unit cord blood transplantation in adult acute myeloid leukemia. International Journal of Hematology, 2021, 113, 840-850.	0.7	7
7	Low diversity of gut microbiota in the early phase of post-bone marrow transplantation increases the risk of chronic graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 1728-1731.	1.3	3
8	Prognostic factors in salvage transplantation for graft failure following allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2021, 56, 2183-2193.	1.3	3
9	Changes in vaccination strategies contribute to the development of invasive pneumococcal disease in allogeneic hematopoietic stem cell transplantation recipients: a retrospective study for promoting vaccination. International Journal of Hematology, 2021, 114, 263-270.	0.7	1
10	Successful Cord Blood Transplantation for Idiopathic CD4 ⁺ Lymphocytopenia. Acta Haematologica, 2021, 144, 698-705.	0.7	1
11	MPL overexpression induces a high level of mutant-CALR/MPL complex: a novel mechanism of ruxolitinib resistance in myeloproliferative neoplasms with CALR mutations. International Journal of Hematology, 2021, 114, 424-440.	0.7	1
12	Donorâ€derived gene mutations in sex chromosome loss after stem cell transplantation. British Journal of Haematology, 2021, 195, e142-e146.	1.2	1
13	Pre-conditioning intervention in patients with relapsed or refractory acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation: a KSGCT multicenter retrospective analysis. Annals of Hematology, 2021, 100, 2763-2771.	0.8	1
14	Fludarabine/busulfan versus busulfan/cyclophosphamide as myeloablative conditioning for myelodysplastic syndrome: a propensity score-matched analysis. Bone Marrow Transplantation, 2021, 56, 3008-3015.	1.3	4
15	Outcome of allogeneic hematopoietic stem cell transplantation for T-cell lymphoblastic leukemia/lymphoma: A single-center study. Leukemia Research, 2021, 108, 106627.	0.4	6
16	Paraplegia via hematogenous dissemination of Cunninghamella elegans (mucormycosis) after hematopoietic stem cell transplantation. International Journal of Infectious Diseases, 2021, 113, 210-212.	1.5	2
17	Nutritional risk index as a risk factor for breakthrough candidemia in allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2020, 55, 661-664.	1.3	5
18	Allogeneic hematopoietic cell transplantation in patients with untreated acute myeloid leukemia: a KSGCT multicenter retrospective analysis. Bone Marrow Transplantation, 2020, 55, 1497-1501.	1.3	1

#	Article	IF	CITATIONS
19	Allogeneic hematopoietic stem cell transplantation for aplastic anemia with preâ€transplant conditioning using fludarabine, reducedâ€dose cyclophosphamide, and lowâ€dose thymoglobulin: A KSGCT prospective study. American Journal of Hematology, 2020, 95, 251-257.	2.0	7
20	Unmanipulated haploidentical hematopoietic stem cell transplantation using very low-dose antithymocyte globulin and methylprednisolone in adults with relapsed/refractory acute leukemia. Annals of Hematology, 2020, 99, 147-155.	0.8	6
21	Safety of total body irradiation using intensity-modulated radiation therapy by helical tomotherapy in allogeneic hematopoietic stem cell transplantation: a prospective pilot study. Journal of Radiation Research, 2020, 61, 969-976.	0.8	12
22	Geriatric nutritional risk index as a useful prognostic factor in second allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1655-1665.	0.8	10
23	Prebiotics protect against acute graft-versus-host disease and preserve the gut microbiota in stem cell transplantation. Blood Advances, 2020, 4, 4607-4617.	2.5	42
24	The impacts of BCR-ABL1 mutations in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who underwent allogeneic hematopoietic cell transplantation. Annals of Hematology, 2020, 99, 2393-2404.	0.8	5
25	Use of unapproved or off-label drugs in Japan for the treatment of graft-versus-host disease and post-transplant viral infection. International Journal of Hematology, 2020, 112, 841-850.	0.7	6
26	T-cell receptor repertoire of cytomegalovirus-specific cytotoxic T-cells after allogeneic stem cell transplantation. Scientific Reports, 2020, 10, 22218.	1.6	7
27	Intraventricular rupture of Aspergillus brain abscess during remission induction. International Journal of Infectious Diseases, 2020, 101, 346-347.	1.5	2
28	Allogeneic hematopoietic cell transplantation for adults with acute myeloid leukemia conducted in Japan during the past quarter century. Annals of Hematology, 2020, 99, 1351-1360.	0.8	26
29	Nontuberculous mycobacterial bloodstream infections after allogeneic hematopoietic stem cell transplantation. International Journal of Infectious Diseases, 2020, 97, 131-134.	1.5	6
30	Sustained Immunogenic and Clinical Effects of Low-Dose Interleukin-2 Therapy with an Intermittent Maintenance Method for Refractory Chronic Graft-Versus-Host Disease: Results of Phase 1/2a LDIL2-01 Study. Biology of Blood and Marrow Transplantation, 2020, 26, S175.	2.0	2
31	Late appearance of eosinophilia in myeloid blast phase of myeloid neoplasm with rearrangement of PDGFRÎ ² . Leukemia and Lymphoma, 2020, 61, 1736-1739.	0.6	0
32	Allogeneic hematopoietic stem cell transplantation for adult patients with B-cell acute lymphoblastic leukemia harboring $t(1;19)(q23;p13.3)$; comparison with normal karyotype. Bone Marrow Transplantation, 2020, 55, 1337-1346.	1.3	4
33	Outcomes and Prognostic Factors for Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Who Underwent Allogeneic Hematopoietic Cell Transplantation: A KSGCT Multicenter Analysis. Biology of Blood and Marrow Transplantation, 2020, 26, 998-1004.	2.0	4
34	The sensitivity of the FLT3-ITD detection method is an important consideration when diagnosing acute myeloid leukemia. Leukemia Research Reports, 2020, 13, 100198.	0.2	7
35	Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia Working Group of the JSHCT. Bone Marrow Transplantation, 2020, 55, 1317-1325.	1.3	14
36	Bone turnover markers as an aid to monitor osteoporosis following allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2020, 99, 1873-1882.	0.8	1

#	Article	IF	CITATIONS
37	Novel Prediction Models of Nonrelapse Mortality in Patients Specific to Each Myeloablative Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation: A Multicenter Analysis from the Kanto Study Group for Cell Therapy (KSGCT). Blood, 2020, 136, 28-29.	0.6	0
38	Significance of FLT3-tyrosine kinase domain mutation as a prognostic factor for acute myeloid leukemia. International Journal of Hematology, 2019, 110, 566-574.	0.7	18
39	The emergence of rare nocardiosis following allogeneic hematopoietic stem cell transplantation in the era of molecular taxonomy. International Journal of Infectious Diseases, 2019, 89, 154-162.	1.5	14
40	Prognostic index for patients with relapsed or refractory acute myeloid leukemia who underwent hematopoietic cell transplantation: a KSGCT multicenter analysis. Leukemia, 2019, 33, 2610-2618.	3.3	12
41	The Authors' Reply to "The Addition of Prophylactic Antibiotics Can Achieve a Favorable Outcome". Internal Medicine, 2019, 58, 2421-2421.	0.3	0
42	Successful hematopoietic stem-cell mobilization with plerixafor plus granulocyte-colony stimulating factor in multiple myeloma patients treated with pomalidomide. International Journal of Hematology, 2019, 110, 115-118.	0.7	2
43	Geriatric nutritional risk index (GNRI) just before allogeneic hematopoietic stem cell transplantation predicts transplant outcomes in patients older than 50Âyears with acute myeloid leukemia in complete remission. Annals of Hematology, 2019, 98, 1799-1801.	0.8	9
44	Efficacy and Safety of a Weekly Cyclophosphamide-Bortezomib-Dexamethasone Regimen as Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myeloma: A Phase 2 Multicenter Trial. Acta Haematologica, 2019, 141, 111-118.	0.7	4
45	Co-activation of macrophages and T cells contribute to chronic GVHD in human IL-6 transgenic humanised mouse model. EBioMedicine, 2019, 41, 584-596.	2.7	20
46	Disseminated adenovirus infection in a patient with relapsed refractory multiple myeloma undergoing autologous stem cell transplantation and pomalidomide/dexamethasone as salvage regimens. Journal of Infection and Chemotherapy, 2019, 25, 371-375.	0.8	5
47	Reassessment of clinical implication of pretransplant surgical procedures for pulmonary invasive fungal lesions. Transplant Infectious Disease, 2019, 21, e13023.	0.7	1
48	Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia. Blood, 2019, 134, 5694-5694.	0.6	1
49	Weight Adjusted Urinary Creatinine Excretion Predicts Transplant Outcomes in Adult Patients with Acute Myeloid Leukemia in Complete Remission. Blood, 2019, 134, 4609-4609.	0.6	0
50	Clonal Dynamics and Publicness of CMV-Specific TCR Repertoire after Allogeneic Stem Cell Transplantation. Blood, 2019, 134, 4551-4551.	0.6	0
51	The Presence of Minimal Residual Disease, As Determined By Highly Sensitive Quantitation of NPM1-Mutatation, Provided Powerful Prognostic Information in Acute Myeloid Leukemia. Blood, 2019, 134, 5097-5097.	0.6	0
52	Clinical and Genetic Characteristics of Adolescent and Young Adult Patients with Myelodysplastic Syndromes. Blood, 2019, 134, 3336-3336.	0.6	0
53	Clinical and Genetic Features of Constitutional Partial Trisomy 8 Mosaicism (CT8M) Patients with Cytopenia. Blood, 2019, 134, 5413-5413.	0.6	0
54	Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response—The final results of the D-first study. Leukemia Research, 2018, 66, 66-72.	0.4	33

#	Article	IF	CITATIONS
55	Outcome of patients with acute undifferentiated leukemia after allogeneic hematopoietic stem cell transplantation. Leukemia and Lymphoma, 2018, 59, 3006-3009.	0.6	10
56	Homozygous HLA-C1 is Associated with Reduced Risk of Relapse after HLA-Matched Transplantation in Patients with Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 717-725.	2.0	21
57	Deferasirox for the treatment of iron overload after allogeneic hematopoietic cell transplantation: multicenter phase I study (KSGCT1302). International Journal of Hematology, 2018, 107, 578-585.	0.7	6
58	Deregulated Mucosal Immune Surveillance through Gut-Associated Regulatory T Cells and PD-1+ T Cells in Human Colorectal Cancer. Journal of Immunology, 2018, 200, 3291-3303.	0.4	28
59	A prospective multicenter phase II study of intrabone marrow transplantation of unwashed cord blood using reducedâ€intensity conditioning. European Journal of Haematology, 2018, 100, 335-343.	1.1	10
60	Prognostic impact of low allelic ratio FLT3-ITD and NPM1 mutation in acute myeloid leukemia. Blood Advances, 2018, 2, 2744-2754.	2.5	106
61	Outcomes after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia harboring t(7;11)(p15;p15). Haematologica, 2018, 103, e69-e72.	1.7	6
62	Fatal Neutropenic Enterocolitis Caused by <i>Stenotrophomonas maltophilia</i> A Rare and Underrecognized Entity. Internal Medicine, 2018, 57, 3667-3671.	0.3	14
63	Allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia with 11q23 abnormality: a retrospective study of the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation (JSHCT). Annals of Hematology, 2018, 97, 2173-2183.	0.8	8
64	Clinical Efficacy of Prebiotics on Transplant-Related Complications. Blood, 2018, 132, 4573-4573.	0.6	1
65	Presence of TP53 Mutation and Monosomal Karyotype Predict the Outcome of Patients with Acute Myeloid Leukemia in Non-Remission at Allogeneic Stem Cell Transplantation. Blood, 2018, 132, 2168-2168.	0.6	1
66	Combining the Number of Infectious Episodes and Interval of Chemotherapy to Transplantation May Predict a Transplant Outcome in Patients with Acute Myeloid Leukemia: A Retrospective Analysis of JALSG AML201 Study. Blood, 2018, 132, 4643-4643.	0.6	0
67	Efficacy and Safety of Once-Weekly Cyclophosphamide-Bortezomib-Dexamethasone (CBD) Regimen As Induction Therapy Prior to Autologous Stem Cell Transplantation in Japanese Patients with Newly Diagnosed Multiple Myelomaa Phase 2 Multicenter Trial Blood, 2018, 132, 2160-2160.	0.6	1
68	Diagnostic open brain biopsy following initial negative results of cerebrospinal fluid assessment for <i><scp>T</scp>oxoplasma</i> . Transplant Infectious Disease, 2017, 19, e12666.	0.7	1
69	Erythrocytosis after allogeneic hematopoietic stem cell transplantation. Clinical Transplantation, 2017, 31, e12918.	0.8	0
70	Central Nervous System Involvement at the Time of Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with a Poor Outcome in Patients with Acute Myeloid Leukemia. Pathology and Oncology Research, 2017, 23, 433-437.	0.9	8
71	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 1517-1523.	0.8	48
72	Impact of Human Leukocyte Antigen Allele Mismatch in Unrelated Bone Marrow Transplantation with Reduced-Intensity Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2017, 23, 300-309.	2.0	12

#	Article	IF	CITATIONS
73	Mycophenolate mofetil is effective only for involved skin in the treatment for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2017, 96, 319-321.	0.8	3
74	Central nervous system infection following allogeneic hematopoietic stem cell transplantation. Hematology/ Oncology and Stem Cell Therapy, 2017, 10, 22-28.	0.6	23
75	Peripheral nerve injury following allogeneic hematopoietic stem cell transplantation. Journal of the Neurological Sciences, 2017, 381, 615.	0.3	0
76	Extramedullary Gastric Relapse at the Time of Bone Marrow Relapse of Acute Lymphoblastic Leukemia after Allogeneic Bone Marrow Transplantation. Internal Medicine, 2017, 56, 3215-3217.	0.3	1
77	Predictive implications of albumin and C-reactive protein for progression to pneumonia and poor prognosis in Stenotrophomonas maltophilia bacteremia following allogeneic hematopoietic stem cell transplantation. BMC Infectious Diseases, 2017, 17, 638.	1.3	18
78	Severe Hypoxemia in a Healthy Donor for Allogeneic Hematopoietic Stem Cell Transplantation after Only the First Administration of Granulocyte-Colony Stimulating Factor. Transfusion Medicine and Hemotherapy, 2016, 43, 433-435.	0.7	5
79	Occurrence of Donor Cell-derived Lymphoid Blast Crisis 24 Years Following Related Bone Marrow Transplantation for Chronic Myeloid Leukemia. Internal Medicine, 2016, 55, 395-397.	0.3	4
80	Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. Blood, 2016, 128, 2083-2088.	0.6	279
81	Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice. Blood, 2016, 127, 722-734.	0.6	39
82	Comparison of transplant outcomes and economic costs between biosimilar and originator filgrastim in allogeneic hematopoietic stem cell transplantation. International Journal of Hematology, 2016, 104, 709-719.	0.7	4
83	Clinical utility of high-flow nasal cannula oxygen therapy for acute respiratory failure in patients with hematological disease. SpringerPlus, 2016, 5, 512.	1.2	22
84	Impacts of graft-versus-host disease on outcomes after allogeneic hematopoietic stem cell transplantation for chronic myelomonocytic leukemia: A nationwide retrospective study. Leukemia Research, 2016, 41, 48-55.	0.4	25
85	Comparison of Outcomes of 8/8 and 7/8 Allele–Matched Unrelated Bone Marrow Transplantation and Single-Unit CordÂBlood Transplantation in Adults with Acute Leukemia. Biology of Blood and Marrow Transplantation, 2016, 22, 330-338.	2.0	100
86	Allogeneic hematopoietic stem cell transplant overcomes poor prognosis of acute myeloid leukemia with myelodysplasia-related changes. Leukemia and Lymphoma, 2016, 57, 76-80.	0.6	19
87	CD25 expression on residual leukemic blasts at the time of allogeneic hematopoietic stem cell transplant predicts relapse in patients with acute myeloid leukemia without complete remission. Leukemia and Lymphoma, 2016, 57, 1375-1381.	0.6	10
88	Association of Peripheral Regulatory T Cells with Achievement of Deep Molecular Response in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia Treated with Dasatinib - the Final Results of D-First Study. Blood, 2016, 128, 1916-1916.	0.6	6
89	Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes. Blood, 2016, 128, 4577-4577.	0.6	0
90	the Safety and Efficacy of Deferasirox for the Transplant Patients with Iron Overload. Blood, 2016, 128, 2254-2254.	0.6	0

#	Article	IF	Citations
91	Growth Suppressing Activity of Lhx2 in Human T Cell Acute Lymphoblastic Leukemia (T-ALL)-Derived Cells and Large-Scale Screening of a Lead Compounds Targeting T-ALL. Blood, 2016, 128, 2813-2813.	0.6	0
92	Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Myeloid Leukemia Harboring t(7;11)(p15;p15). Blood, 2016, 128, 4654-4654.	0.6	0
93	The Clinical Outcome of Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) for Elderly Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) in the Era of Tyrosine Kinase Inhibitor (TKI): A Single Institute Experience. Biology of Blood and Marrow Transplantation, 2015, 21. S279.	2.0	0
94	Toxic encephalopathy after exposure to azacitidine. Leukemia and Lymphoma, 2015, 56, 1538-1539.	0.6	2
95	Clinical impact of hematogones on outcomes of allogeneic hematopoietic stem cell transplantation. Annals of Hematology, 2015, 94, 2055-2060.	0.8	11
96	Early-onset acute kidney injury is a poor prognostic sign for allogeneic SCT recipients. Bone Marrow Transplantation, 2015, 50, 1557-1562.	1.3	33
97	Postâ€transplant maintenance therapy with azacitidine and gemtuzumab ozogamicin for highâ€tisk acute myeloid leukaemia. British Journal of Haematology, 2015, 169, 756-759.	1.2	48
98	Retrospective Evaluation of Incidence and Prognostic Factors for Stenotrophomonas Maltophilia Bacteremia Following Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2015, 126, 4626-4626.	0.6	0
99	Urinary Liver-Type Fatty Acid-Binding Protein Linked with Increased Risk of Acute Kidney Injury after Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2014, 20, 2010-2014.	2.0	21
100	Clinical Impact of CD25 Expression of Leukemic Blasts on Subsequent Transplant Outcomes in Patients with Refractory or Relapsed Acute Myeloid Leukemia. Blood, 2014, 124, 2589-2589.	0.6	0
101	An Increase in Baseline Level of Urinary Liver-Type Fatty Acid-Binding Protein Linked with Poor Prognosis after Allogeneic Hematopoietic Stem Cell Transplantation. Blood, 2014, 124, 3861-3861.	0.6	0
102	A Pyrrolo-Pyrimidine Derivative Targets Human Primary AML Stem Cells in Vivo. Science Translational Medicine, 2013, 5, 181ra52.	5.8	75
103	Contribution of Bone Marrow-Derived Hematopoietic Stem/Progenitor Cells to the Generation of Donor-Marker+ Cardiomyocytes In Vivo. PLoS ONE, 2013, 8, e62506.	1.1	18
104	Il2rg Gene-Targeted Severe Combined Immunodeficiency Pigs. Cell Stem Cell, 2012, 10, 753-758.	5.2	143
105	Incidence, risk factors, and clinical outcomes of cataracts following hematopoietic stem cell transplantation. American Journal of Hematology, 2011, 86, 508-510.	2.0	10
106	Molecular monitoring of BAALC expression in patients with CD34-positive acute leukemia. International Journal of Hematology, 2010, 91, 636-645.	0.7	17
107	Generation of functional human T-cell subsets with HLA-restricted immune responses in HLA class I expressing NOD/SCID/IL2rγ ^{null} humanized mice. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 13022-13027.	3.3	348
108	Identification of Therapeutic Targets for Quiescent, Chemotherapy-Resistant Human Leukemia Stem Cells. Science Translational Medicine, 2010, 2, 17ra9.	5.8	364

#	Article	IF	CITATIONS
109	Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nature Biotechnology, 2010, 28, 275-280.	9.4	373
110	Intracranial hemorrhage following allogeneic hematopoietic stem cell transplantation. American Journal of Hematology, 2009, 84, 298-301.	2.0	37
111	Molecular Monitoring of ERG and BAALC as Minimal Residual Disease Markers in Patients with Acute Leukemia Blood, 2007, 110, 4249-4249.	0.6	0
112	High Mobility Group Protein-B1 Interacts with Sterol Regulatory Element-binding Proteins to Enhance Their DNA Binding. Journal of Biological Chemistry, 2005, 280, 27523-27532.	1.6	36
113	p53 Involvement in the Pathogenesis of Fatty Liver Disease. Journal of Biological Chemistry, 2004, 279, 20571-20575.	1.6	106
114	p53 Activation in Adipocytes of Obese Mice. Journal of Biological Chemistry, 2003, 278, 25395-25400.	1.6	180